Common in Inflammatory Genes Interleukin ( IL ) 6 , IL8 , Tumor Necrosis Factor (cid:1) , NFKB1 , and Peroxisome Proliferator-activated Receptor (cid:2) with Colorectal Cancer

Animal models and epidemiological observations suggest that a contin- uous inflammatory condition predisposes to colorectal cancer (CRC), but the roles of different elements participating in inflammatory responses have been little investigated in relation to CRC. We have studied the association between single nucleotide polymorphisms in the interleukin ( IL ) -6 ( (cid:3) 174 G > C), IL8 ( (cid:3) 251T > A), tumor necrosis factor (cid:1) ( (cid:3) 308G > A), and PPARG (Pro12Ala) genes and the risk of CRC in a group of 377 cases and 326 controls from Barcelona, Spain. These genes are known to be important for inflammation of the colorectum and common allelic variants have been shown to have a biological effect. The PPARG Ala12 and IL8 -251A genotypes are associated with reduced risk of disease (0.56, 95% CI, 0.37–0.85, P (cid:4) 0.0056, and 0.70, 95% CI, 0.50– 0.99, P (cid:4) 0.043, respectively), whereas the IL6 –174C genotype is associated with increased risk (1.53, 95% CI, 1.12–2.09, P (cid:4) 0.0073). We also studied a single nucleotide polymorphism in intron 11 of the NFKB1 gene (rs1020759), which probably lacks any functional role, and found no significant association with the disease. This is the first report that IL6 , IL8 , and PPARG genes are important in relation to inflammation-related risk of sporadic CRC.

[1]  F. Pociot,et al.  Cytokine gene polymorphism in human disease: on-line databases, Supplement 2 , 2002, Genes and Immunity.

[2]  J Hart,et al.  Inflammation. 1: Its role in the healing of acute wounds. , 2002, Journal of wound care.

[3]  G. Chrousos,et al.  Stress Hormones, Proinflammatory and Antiinflammatory Cytokines, and Autoimmunity , 2002, Annals of the New York Academy of Sciences.

[4]  H. Ahorn,et al.  N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth , 2002, Oncogene.

[5]  R. Zinkernagel,et al.  Arterial inflammation and atherosclerosis. , 2002, Trends in cardiovascular medicine.

[6]  P. Weber,et al.  Phytanic acid, a natural peroxisome proliferator‐activated receptor agonist, regulates glucose metabolism in rat primary hepatocytes , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  T. Pritts,et al.  Mucosal and enterocyte IL-6 production during sepsis and endotoxemia--role of transcription factors and regulation by the stress response. , 2002, American journal of surgery.

[8]  B. Epe,et al.  Influence of nitric oxide on the generation and repair of oxidative DNA damage in mammalian cells. , 2002, Carcinogenesis.

[9]  M. Lathrop,et al.  Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. , 2002, Cardiovascular research.

[10]  Y. Matsuzawa,et al.  Peroxisome proliferator-activated receptor gamma reduces the growth rate of pancreatic cancer cells through the reduction of cyclin D1. , 2002, Life sciences.

[11]  S. Weitzman,et al.  Chronic inflammation and cancer. , 2002, Oncology.

[12]  V. Vallyathan,et al.  Diseases caused by asbestos: mechanisms of injury and disease development. , 2002, International immunopharmacology.

[13]  M. Moore.  Cytokine and chemokine networks influencing stem cell proliferation, differentiation, and marrow homing , 2002, Journal of cellular biochemistry. Supplement.

[14]  J. Rhodes,et al.  Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. , 2002, Trends in molecular medicine.

[15]  P. Vineis,et al.  Metabolic gene polymorphism frequencies in control populations. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[16]  E. Hawe,et al.  The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. , 2001, European heart journal.

[17]  A. Rumley,et al.  Interleukin-6 Gene −174G>C and −572G>C Promoter Polymorphisms Are Strong Predictors of Plasma Interleukin-6 Levels After Coronary Artery Bypass Surgery , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[18]  A. Nakajima,et al.  PPARγ and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease , 2001 .

[19]  S. Cannistra,et al.  Opposite association of two PPARG variants with cancer: overrepresentation of H449H in endometrial carcinoma cases and underrepresentation of P12A in renal cell carcinoma cases , 2001, Human Genetics.

[20]  M. Stumvoll,et al.  Insulin Resistance and Insulin Sensitizers , 2001, Hormone Research in Paediatrics.

[21]  J. Chun,et al.  The -238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. , 2001, Cancer letters.

[22]  J. Powell,et al.  Interleukin-6 (IL-6) and the Prognosis of Abdominal Aortic Aneurysms , 2001, Circulation.

[23]  Takuji Tanaka,et al.  Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. , 2001, Cancer research.

[24]  S. Nomoto,et al.  Polymorphism of tumor necrosis factor in esophageal, gastric or colorectal carcinoma. , 2001, Hepato-gastroenterology.

[25]  G. Fantuzzi,et al.  Production of IL‐1 receptor antagonist by hepatocytes is regulated as an acute‐phase protein in vivo , 2001, European journal of immunology.

[26]  坪内 康則.  Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonists through induction of apoptosis , 2001 .

[27]  K. Ley.  Pathways and bottlenecks in the web of inflammatory adhesion molecules and chemoattractants , 2001, Immunologic research.

[28]  A. Nusrat,et al.  Interaction of bacteria and bacterial toxins with intestinal epithelial cells , 2001, Current gastroenterology reports.

[29]  D. Kwiatkowski,et al.  Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families , 2000, Thorax.

[30]  E. Riboli,et al.  Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. , 2000, Journal of the National Cancer Institute.

[31]  B. Staels,et al.  Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation , 2000, Inflammation Research.

[32]  Eric S. Lander,et al.  The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes , 2000, Nature Genetics.

[33]  J. Gilbert,et al.  SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. , 2000, American journal of human genetics.

[34]  F. Green,et al.  Cooperative Influence of Genetic Polymorphisms on Interleukin 6 Transcriptional Regulation* , 2000, The Journal of Biological Chemistry.

[35]  C. Plass,et al.  Over-representation of PPARγ sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population , 2000, Journal of medical genetics.

[36]  Miller,et al.  Experimental evidence from an animal model of adenocarcinoma that chronic inflammation enhances lung cancer risk , 2000, Chest.

[37]  G. Gores,et al.  Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. , 2000, Cancer research.

[38]  S. Steinberg,et al.  An IL 6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus , 2000 .

[39]  A. Watson,et al.  Lessons from genetically engineered animal models. VII. Apoptosis in intestinal epithelium: lessons from transgenic and knockout mice. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[40]  D. Malo,et al.  The Lps locus: Genetic regulation of host responses to bacterial lipopolysaccharide , 1999, Inflammation Research.

[41]  G. Hannon,et al.  A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity , 1999, The Journal of experimental medicine.

[42]  R. Pounder,et al.  Helicobacter pylori: from the benign to the malignant. , 1999, The American journal of gastroenterology.

[43]  K. Okita,et al.  Metaplastic polyp of the colon develops in response to inflammation , 1999, Journal of gastroenterology and hepatology.

[44]  B. Spiegelman,et al.  Loss-of-Function Mutations in PPARγ Associated with Human Colon Cancer , 1999 .

[45]  J. McCann.  Esophageal cancers: changing character, increasing incidence. , 1999, Journal of the National Cancer Institute.

[46]  Y. Matsuzawa,et al.  Peroxisome Proliferator‐activated Receptor γ Induces Growth Arrest and Differentiation Markers of Human Colon Cancer Cells , 1999, Japanese journal of cancer research : Gann.

[47]  R. Macdermott,et al.  Increased interleukin-8 (IL-8) in rectal dialysate from patients with ulcerative colitis: evidence for a biological role for IL-8 in inflammation of the colon , 1999, American Journal of Gastroenterology.

[48]  S. Mayne,et al.  Previous lung disease and risk of lung cancer among men and women nonsmokers. , 1999, American journal of epidemiology.

[49]  Johan Auwerx,et al.  A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity , 1998, Nature Genetics.

[50]  J S Yudkin,et al.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. , 1998, The Journal of clinical investigation.

[51]  V. Perry,et al.  The contribution of inflammation to acute and chronic neurodegeneration. , 1998, Research in immunology.

[52]  Samuel Singer,et al.  Differentiation and reversal of malignant changes in colon cancer through PPARγ , 1998, Nature Medicine.

[53]  H P Koeffler,et al.  Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. , 1998, Cancer research.

[54]  H P Koeffler,et al.  Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[55]  J. Mok,et al.  Analysis of TNFB and TNFA NcoI RFLP in colorectal cancer. , 1998, Molecules and cells.

[56]  J. Auwerx,et al.  The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene* , 1997, The Journal of Biological Chemistry.

[57]  D. Willoughby,et al.  The codependence of angiogenesis and chronic inflammation , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[58]  H. Mcdevitt,et al.  Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[59]  Relative validity and reproducibility of a diet history questionnaire in Spain. II. Nutrients. EPIC Group of Spain. European Prospective Investigation into Cancer and Nutrition. , 1997, International journal of epidemiology.

[60]  Y. Arakawa,et al.  Helicobacter pylori, neutrophils, interleukins, and gastric epithelial proliferation. , 1997, Journal of clinical gastroenterology.

[61]  Relative validity and reproducibility of a diet history questionnaire in Spain. I. Foods. EPIC Group of Spain. European Prospective Investigation into Cancer and Nutrition. , 1997, International journal of epidemiology.

[62]  P. O'connor,et al.  Role of schistosomiasis in human bladder cancer: evidence of association, aetiological factors, and basic mechanisms of carcinogenesis. , 1995, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[63]  R. Coffey,et al.  Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.

[64]  C. la Vecchia,et al.  Alcohol and the risk of cancers of the stomach and colon-rectum. , 1994, Digestive diseases.

[65]  R. Cortese,et al.  The two C/EBP isoforms, IL-6DBP/NF-IL6 and C/EBP delta/NF-IL6 beta, are induced by IL-6 to promote acute phase gene transcription via different mechanisms. , 1993, Nucleic acids research.

[66]  L. Sachs,et al.  Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[67]  K J Rothman,et al.  No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.

[68]  L. Schwartz,et al.  Inflammatory mediators of experimental colitis in rats. , 1989, Gastroenterology.

[69]  R. Day,et al.  Non-steroidal anti-inflammatory drugs , 2019, Reactions Weekly.

[70]  G PLACITELLI,et al.  [Ulcerative colitis]. , 1958, La Riforma medica.